АРТ в 2016-2017 гг: неизменная потребность в индивидуализации лечения для улу...hivlifeinfo
In this downloadable slideset, Danielle Ciuffetelli, PharmD, and Elly Fatehi, PharmD, BCPS, review important considerations when selecting initial ART and explore how formularies can be better managed to ensure delivery of optimal care for diverse populations of HIV-infected patients. Illustrative cases provide useful examples of key factors involved in treatment selection, including comorbidities, patient preferences and disposition, concomitant medications, and childbearing potential.
Format: Microsoft PowerPoint (.ppt)
File size: 2.46 MB
Date posted: 1/10/2017
Choosing Among Current Antiretroviral Regimens.The Relevance of Drug–Drug Int...hivlifeinfo
In this downloadable slideset, Jürgen K. Rockstroh, MD, reviews how selection of antiretroviral therapy is influenced by drug–drug interactions and differing antiretroviral genetic barriers to resistance.
Format: Microsoft PowerPoint (.ppt)
File size: 1.17 MB
Date posted: 11/4/2016
Dr. Leroy Hood lectured to a group of Ohio State University College of Medicine students and faculty on May 13, 2010 in advance of an announcement of a partnership between the Ohio State University Medical Center and the Institute for Systems Biology. The partnership will be known as
Confronting the Challenges of HIV Care in an Aging Population.2019hivlifeinfo
Еxpert faculty use case-based examples to examine considerations for aging patients with HIV. Topics include ART modification, bone loss, renal impairment, cardiovascular risk, and cognitive decline.
Современное лечение ВИЧ: модификация АРТ у пациентов с вирусной супрессией и ...hivlifeinfo
Современное лечение ВИЧ: модификация АРТ у пациентов с вирусной супрессией и у пациентов с вирусологической неудачей. /Contemporary Management of HIV. Modifying Antiretroviral Therapy in Virologically Suppressed Patients and Those With Treatment Failure.2016
In this downloadable slideset, W. David Hardy, MD, and Program Director Eric S. Daar, MD review key data and optimal approaches for modifying ART in patients who are virologically suppressed or have experienced treatment failure.
Format: Microsoft PowerPoint (.ppt)
File size: 2.07 MB
АРТ в 2016-2017 гг: неизменная потребность в индивидуализации лечения для улу...hivlifeinfo
In this downloadable slideset, Danielle Ciuffetelli, PharmD, and Elly Fatehi, PharmD, BCPS, review important considerations when selecting initial ART and explore how formularies can be better managed to ensure delivery of optimal care for diverse populations of HIV-infected patients. Illustrative cases provide useful examples of key factors involved in treatment selection, including comorbidities, patient preferences and disposition, concomitant medications, and childbearing potential.
Format: Microsoft PowerPoint (.ppt)
File size: 2.46 MB
Date posted: 1/10/2017
Choosing Among Current Antiretroviral Regimens.The Relevance of Drug–Drug Int...hivlifeinfo
In this downloadable slideset, Jürgen K. Rockstroh, MD, reviews how selection of antiretroviral therapy is influenced by drug–drug interactions and differing antiretroviral genetic barriers to resistance.
Format: Microsoft PowerPoint (.ppt)
File size: 1.17 MB
Date posted: 11/4/2016
Dr. Leroy Hood lectured to a group of Ohio State University College of Medicine students and faculty on May 13, 2010 in advance of an announcement of a partnership between the Ohio State University Medical Center and the Institute for Systems Biology. The partnership will be known as
Confronting the Challenges of HIV Care in an Aging Population.2019hivlifeinfo
Еxpert faculty use case-based examples to examine considerations for aging patients with HIV. Topics include ART modification, bone loss, renal impairment, cardiovascular risk, and cognitive decline.
Современное лечение ВИЧ: модификация АРТ у пациентов с вирусной супрессией и ...hivlifeinfo
Современное лечение ВИЧ: модификация АРТ у пациентов с вирусной супрессией и у пациентов с вирусологической неудачей. /Contemporary Management of HIV. Modifying Antiretroviral Therapy in Virologically Suppressed Patients and Those With Treatment Failure.2016
In this downloadable slideset, W. David Hardy, MD, and Program Director Eric S. Daar, MD review key data and optimal approaches for modifying ART in patients who are virologically suppressed or have experienced treatment failure.
Format: Microsoft PowerPoint (.ppt)
File size: 2.07 MB
Expert Insights in Selecting a Switch Regimen for Virologically Suppressed HI...hivlifeinfo
Expert Insights in Selecting a Switch Regimen for Virologically Suppressed HIV-Infected Patients.2018
In this slideset, Babafemi Taiwo, MBBS, discusses expert approaches to selecting an HIV switch regimen in a series of cases studies involving HIV-infected patients with virologic suppression on their current ART regimen.
Format: Microsoft PowerPoint (.ppt)
File Size: 1.10 MB
In this downloadable slideset, Joel E. Gallant, MD, MPH, reviews the evidence behind the latest antiretroviral guidelines and offers a glimpse at upcoming agents currently under investigation.
Format: Microsoft PowerPoint (.ppt)
File size: 3.00 MB
Date posted: 6/15/2015
HIV Alert: Best Practices in ART Following Recent Drug Approvals.2016hivlifeinfo
In this downloadable slideset, Eric S. Daar, MD, and Joel E. Gallant, MD, MPH, review best practices and provide expert opinion in using newly approved ART options for treating patients with HIV.
Format: Microsoft PowerPoint (.ppt)
File size: 816 KB
Date posted: 5/12/2016
Clinical Impact of New HIV Data From CROI 2019hivlifeinfo
March 4-7, 2019; Seattle, Washington
In this downloadable slideset, expert faculty members summarize key studies from this important annual conference.
Format: Microsoft PowerPoint (.ppt)
File Size: 576 KB
Released: March 22, 2019
Key Slides on ART for HIV : Evolving Concepts and Innovative Strategies.2020hivlifeinfo
Expert-authored slides on evolving ART concepts, including simplification to 2-drug therapy, ART safety during pregnancy, weight gain, and long-acting injectable ART.
File Size: 580 KB
Released: October 20, 2020
Современное лечение ВИЧ: модификация АРТ у пациентов с вирусологической супре...hivlifeinfo
Современное лечение ВИЧ: модификация АРТ у пациентов с вирусологической супрессией (2021) / Contemporary Management of HIV: Modifying ART in Virologically Suppressed Patients 2021
HIV Alert:ART Considerations for Aging Patients.2018hivlifeinfo
In this downloadable slideset, Eric S. Daar, MD, and David A. Wohl, MD, provide expert recommendations for older patients with HIV, both in terms of ART selection and general management.
Format: Microsoft PowerPoint (.ppt)
File size: 545 KB
Date posted: 2/12/2018
Современное лечение ВИЧ: новые парадигмы в АРТ / Contemporary Management of H...hivlifeinfo
Набор слайдов c рассмотрением важных вопросов об АРТ первого ряда, арв-препаратами пролонгированного действия и схемами АРТ с двумя препаратами, акцент в публикации на роль новых стратегий.
HIV Alert :Updating Your Practice Based on New Guideline Recommendations.2016hivlifeinfo
In this downloadable slideset, Eric S. Daar, MD, and Paul E. Sax, MD, review recent updates to expert guideline recommendations for ART—including new initial therapy recommendations, revised guidance on switch strategies for virologically suppressed patients, and other key recommendation updates.
Format: Microsoft PowerPoint (.ppt)
File size: 1.09 MB
Date posted: 9/19/2016
Ключевые слайды по индивидуальному выбору АРТ / Key Slides on Individualized ...hivlifeinfo
Слайды с последними данные и рекомендациями по выбору АРТ, как для пациентов, ранее не получавших лечения, так и пациентов с вирусологической супрессией. Оценки разных вариантов лечения, индивидуализация АРТ для женщин детородного возраста и во время беременности, пациентов с опортунистическими инфекциями и новые данные об исследовательских стратегиях АРТ.
In this downloadable slideset, Joseph J. Eron, Jr., MD, reviews the evidence behind the latest antiretroviral guidelines and offers a glimpse at potential future agents and strategies currently under investigation.
Format: Microsoft PowerPoint (.ppt)
File size: 2.06 MB
Date posted: 6/1/2016
Оптимизация лечения ВИЧ в 2018 году / HIV Treatment Optimization: 2018hivlifeinfo
HIV Treatment Optimization: 2018
In this downloadable slideset, Eric S. Daar, MD, provides a comprehensive update on ART management.
Format: Microsoft PowerPoint (.ppt)
File Size: 723 KB
Released: April 26, 2018
Pharmacy Essentials for HIV Screening and Management.2019hivlifeinfo
Pharmacy Essentials for HIV Screening and Management
This downloadable slideset provides an in-depth review of key pharmacy strategies for expanding and supporting safe and effective HIV screening and treatment services to patients at risk of or living with HIV infection.
Jennifer Cocohoba Headshot
Jennifer Cocohoba, PharmD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.93 MB
Released: January 31, 2019
Новые данные с конференции по ВИЧ-инфекции CROI 2017/Clinical Impact of New D...hivlifeinfo
Clinical Impact of New Data From CROI 2017
Expert faculty members Joel E. Gallant, MD, MPH, and Charles B. Hicks, MD, summarize key studies from this important annual conference.
Format: Microsoft PowerPoint (.ppt)
File size: 1.25 MB
Date posted: 3/3/2017
These slides use concepts from my (Jeff Funk) course entitled Biz Models for Hi-Tech Products to analyze the business model for 23andMe’s personal genomics service. 23andMe provides personal health care analysis and ancestry information to individuals that are based on a partial analysis of an individual’s DNA data. Driven by the falling cost of DNA sequencing, 23 and Me provides this information for $99 and a small amount of saliva. While this business model may succeed particularly if the FDA eventually approves the health care portion of the service, we recommend that 23andMe develop a new business model. It should offer the service for free to individuals, particularly those who frequent gyms and nutrition stores and sell information about potential athletes to sports teams.
Expert Insights in Selecting a Switch Regimen for Virologically Suppressed HI...hivlifeinfo
Expert Insights in Selecting a Switch Regimen for Virologically Suppressed HIV-Infected Patients.2018
In this slideset, Babafemi Taiwo, MBBS, discusses expert approaches to selecting an HIV switch regimen in a series of cases studies involving HIV-infected patients with virologic suppression on their current ART regimen.
Format: Microsoft PowerPoint (.ppt)
File Size: 1.10 MB
In this downloadable slideset, Joel E. Gallant, MD, MPH, reviews the evidence behind the latest antiretroviral guidelines and offers a glimpse at upcoming agents currently under investigation.
Format: Microsoft PowerPoint (.ppt)
File size: 3.00 MB
Date posted: 6/15/2015
HIV Alert: Best Practices in ART Following Recent Drug Approvals.2016hivlifeinfo
In this downloadable slideset, Eric S. Daar, MD, and Joel E. Gallant, MD, MPH, review best practices and provide expert opinion in using newly approved ART options for treating patients with HIV.
Format: Microsoft PowerPoint (.ppt)
File size: 816 KB
Date posted: 5/12/2016
Clinical Impact of New HIV Data From CROI 2019hivlifeinfo
March 4-7, 2019; Seattle, Washington
In this downloadable slideset, expert faculty members summarize key studies from this important annual conference.
Format: Microsoft PowerPoint (.ppt)
File Size: 576 KB
Released: March 22, 2019
Key Slides on ART for HIV : Evolving Concepts and Innovative Strategies.2020hivlifeinfo
Expert-authored slides on evolving ART concepts, including simplification to 2-drug therapy, ART safety during pregnancy, weight gain, and long-acting injectable ART.
File Size: 580 KB
Released: October 20, 2020
Современное лечение ВИЧ: модификация АРТ у пациентов с вирусологической супре...hivlifeinfo
Современное лечение ВИЧ: модификация АРТ у пациентов с вирусологической супрессией (2021) / Contemporary Management of HIV: Modifying ART in Virologically Suppressed Patients 2021
HIV Alert:ART Considerations for Aging Patients.2018hivlifeinfo
In this downloadable slideset, Eric S. Daar, MD, and David A. Wohl, MD, provide expert recommendations for older patients with HIV, both in terms of ART selection and general management.
Format: Microsoft PowerPoint (.ppt)
File size: 545 KB
Date posted: 2/12/2018
Современное лечение ВИЧ: новые парадигмы в АРТ / Contemporary Management of H...hivlifeinfo
Набор слайдов c рассмотрением важных вопросов об АРТ первого ряда, арв-препаратами пролонгированного действия и схемами АРТ с двумя препаратами, акцент в публикации на роль новых стратегий.
HIV Alert :Updating Your Practice Based on New Guideline Recommendations.2016hivlifeinfo
In this downloadable slideset, Eric S. Daar, MD, and Paul E. Sax, MD, review recent updates to expert guideline recommendations for ART—including new initial therapy recommendations, revised guidance on switch strategies for virologically suppressed patients, and other key recommendation updates.
Format: Microsoft PowerPoint (.ppt)
File size: 1.09 MB
Date posted: 9/19/2016
Ключевые слайды по индивидуальному выбору АРТ / Key Slides on Individualized ...hivlifeinfo
Слайды с последними данные и рекомендациями по выбору АРТ, как для пациентов, ранее не получавших лечения, так и пациентов с вирусологической супрессией. Оценки разных вариантов лечения, индивидуализация АРТ для женщин детородного возраста и во время беременности, пациентов с опортунистическими инфекциями и новые данные об исследовательских стратегиях АРТ.
In this downloadable slideset, Joseph J. Eron, Jr., MD, reviews the evidence behind the latest antiretroviral guidelines and offers a glimpse at potential future agents and strategies currently under investigation.
Format: Microsoft PowerPoint (.ppt)
File size: 2.06 MB
Date posted: 6/1/2016
Оптимизация лечения ВИЧ в 2018 году / HIV Treatment Optimization: 2018hivlifeinfo
HIV Treatment Optimization: 2018
In this downloadable slideset, Eric S. Daar, MD, provides a comprehensive update on ART management.
Format: Microsoft PowerPoint (.ppt)
File Size: 723 KB
Released: April 26, 2018
Pharmacy Essentials for HIV Screening and Management.2019hivlifeinfo
Pharmacy Essentials for HIV Screening and Management
This downloadable slideset provides an in-depth review of key pharmacy strategies for expanding and supporting safe and effective HIV screening and treatment services to patients at risk of or living with HIV infection.
Jennifer Cocohoba Headshot
Jennifer Cocohoba, PharmD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.93 MB
Released: January 31, 2019
Новые данные с конференции по ВИЧ-инфекции CROI 2017/Clinical Impact of New D...hivlifeinfo
Clinical Impact of New Data From CROI 2017
Expert faculty members Joel E. Gallant, MD, MPH, and Charles B. Hicks, MD, summarize key studies from this important annual conference.
Format: Microsoft PowerPoint (.ppt)
File size: 1.25 MB
Date posted: 3/3/2017
These slides use concepts from my (Jeff Funk) course entitled Biz Models for Hi-Tech Products to analyze the business model for 23andMe’s personal genomics service. 23andMe provides personal health care analysis and ancestry information to individuals that are based on a partial analysis of an individual’s DNA data. Driven by the falling cost of DNA sequencing, 23 and Me provides this information for $99 and a small amount of saliva. While this business model may succeed particularly if the FDA eventually approves the health care portion of the service, we recommend that 23andMe develop a new business model. It should offer the service for free to individuals, particularly those who frequent gyms and nutrition stores and sell information about potential athletes to sports teams.
A Lightning Round presentation for the University of Michigan's Emergent Research Series, July 23, 2016, presenting recent work from the MLA Systematic Review Team 6 on Emerging Technologies.
An overview of the current regulatory environment. *This is not legal advice and is written by a non-attorney. This is general information from a student in law school (MSJ program).
This is Part 1 of a presentation on Genetic Toxicology that was given by Dr. David Kirkland to scientific staff at Health Canada in Sept. 2010. Part 2 is availabile in ppt
DNA Roulette: Understanding genetics and genetic testing through gamingcarrie.heeter
DNA Roulette was developed by Michigan State University professor Carrie Heeter and Stanford geneticist Barry Starr to help players understand what Direct to Consumer (DTC) testing does and does not tell you about your health. This presentation at Games for Health 2012 in Boston introduces the game.
Regulatory oversight of genetic testing in Canada: Health Canada perspectiveMaRS Discovery District
Speaker: Patrice Sarrazin, PhD, Senior Scientific Evaluator, In Vitro Diagnostic Devices, Medical Devices Bureau, Therapeutic Product Directorate, Health Canada. Patrice discusses Health Canada's perspective on genetic testing as well as policy and regulation in Canada.
Part of Dx2010, a workshop at MaRS focused on best practices and regulatory considerations for developing gene-based diagnostic and prognostic tests.
Direct To Consumer Genomics and the Future of HealthcareRyan Squire
Richard Sharp, Ph.D., Director of Bioethics Research at the Cleveland Clinic presents on direct-to-consumer genomics and the future of health care.
Dr. Sharp received his training in philosophy and medical ethics at Michigan State University.
Prior to joining the Cleveland Clinic in 2007, Dr. Sharp taught bioethics at Baylor College of Medicine and the National Institute of Environmental Health Sciences, one of the National Institutes of Health (NIH), where he directed the Program in Environmental Health Policy and Ethics.
His research examines the promotion of informed patient decision-making in clinical research, particularly research that involves genetic analyses.
Medical Utopias: The Promise of Emerging TechnologiesAlex Tang
Medical utopias are often about good health, absence of suffering, and even delaying of the aging process. The last two decades have seen a tremendous increase in emerging medical technologies to achieve these utopias. The completion of the sequencing of the human genome sets the stage for the next step of genetic and molecular advances. The increase in computing power, storage capacity, connectivity, and the Internet has opened avenues of new diagnostic and therapeutic modalities. The perfecting of sustaining cell growth in vitro and cell nucleus transfer has opened the way to cloning, stem cell harvesting, and a new field of regenerative medicine. However, these emerging technologies bring with them a large number of bioethical concerns that need to be addressed. These concerns involving tissue engineering, bioelectronics, new genetics, cloning, gene therapy, germ-line genome modifications are only the tip of the iceberg. In this paper I will reflect on three areas of concern. Firstly, the emergence of the digital patient will be considered. This digital patient will be deeply formed and informed by health information technology (IT), the social media, and issues involving privacy, confidentiality and data security. Secondly, the direct to customers (DTC) genetic screening tests will be discussed. The ethical issue of buccal swabs taken at home and be tested for genetic diseases and future prediction of other illnesses which is marketed directly to the consumers will be examined. Finally, the development of new pharmaco-therapeutics will be explored. There have been changes in the way new drugs are tested and these changes do raise some ethical concerns. The examination of these ethical issues will be done in the framework of respect for autonomy, beneficence, non-maleficence, and justice.
A look at future directions for biology. Personalized genomics is a key step in moving towards individualized medicine and preventative interventions. The traditional trial and error approach of molecular biology is being replaced by the direct design of synthetic biology. Synthetically developed energy solutions could have a substantial impact on natural resource demand.
You're driving down the highway, when suddenly you spot a police officer or a state trooper in your rearview mirror. You're driving the speed limit; your tags are up-to-date, yet you suddenly feel guilty – like you've done something wrong.
This is how the FDA makes us feel when it comes to running direct-to-consumer (DTC) advertising for medical devices and pharmaceuticals. More often than not, you aren't doing anything wrong. But your anxiety levels run high as soon as you step on the gas.
Personalized medicine involves the prescription of specific therapeutics best suited for an individual based on their genetic or proteomic profile. This talk discusses current approaches in drug discovery/development, the role of genetics in drug metabolism, and lawful/ethical issues surrounding the deployment of new health technology. I highlight some bioinformatic roles in the drug discovery process, and discuss the use of semantic web technologies for data integration and knowledge discovery..
On April 5, 2014 the MRF partnered with Seattle Cancer Care Alliance and Fred Hutchinson Cancer Research Center to provide a free educational event dedicated to melanoma patients and the people who support them.
Contemporary Management of HIV.How Common Comorbidities Affect ART Management...hivlifeinfo
In this downloadable slideset, expert faculty review key data and offer important guidance on managing HIV treatment in patients with frequently encountered comorbidities, including cardiovascular disease, osteopenia, and HCV coinfection.
Format: Microsoft PowerPoint (.ppt)
File size: 2.27 MB
Date posted: 2/12/2018
Supporting Genomics in the Practice of Medicine by Heidi RehmKnome_Inc
View the webinar at http://www.knome.com/webinar-supporting-genomics-practice-medicine. In this presentation, Dr. Heidi Rehm, Chief Laboratory Director of the Laboratory for Molecular Medicine at Partners Healthcare and one of the Principal Investigators on ClinGen, elucidates the challenges of genomics in medicine and outlined the path to integrating large scale sequencing into clinical practice.
Discovered by Eloise Giblett in 1972.
ADA deficiency or ADA-SCID or Bubble boy disorder.
Recognized as the first immunodeficiency disorder.
Accounts for 10-15% of all cases of SCID.
An autosomal recessive metabolic disorder causes immunodeficiency.
Rare occurring disease.
Both males and females are equally affected.
All racial and ethnic groups are affected
Personalized medicine involves the prescription of specific therapeutics best suited for an individual based on their genetic or proteomic profile. This talk discusses current approaches in drug discovery/development, the role of genetics in drug metabolism, and lawful/ethical issues surrounding the deployment of new health technology.
Overview and Pharmacotherapy of Prostate Cancer (based on NCCN 2012 guideline...hyunik116
This presentation was the prostate cancer lecture for the oncology therapeutics course (31:725:560) that was presented to the class of 2014 PharmD students at the Ernest Mario School of Pharmacy.
I really enjoyed researching and preparing this lecture for the students, and hope you also will find at least something useful in this presentation.
Современное лечение и профилактика ВИЧ : передовые стратегии лечения у пациен...hivlifeinfo
Стратегии смены АРТ у пациентов с вирусной супрессией, включая смену АРТ при резистентности, рекомендации по инъекционным препаратам длительного действия , смена АРТ до или во время беременности
PDCD is an abbreviation for pyruvate dehydrogenase complex deficiency, a genetic mitochondrial disorder in children which is frequently associated with lactic acidosis and neurological/neuromuscular symptoms.
Современное лечение ВИЧ: лечение ВИЧ у женщин.2017/Contemporary Management of...hivlifeinfo
In this downloadable slideset, Kathleen E. Squires, MD, and Program Director Joseph J. Eron, Jr., MD, review key data and optimal strategies in caring for HIV-infected women, including ART safety and efficacy in women, reproductive health management, ART and pregnancy, and preventing HIV infection in women.
Format: Microsoft PowerPoint (.ppt)
File size: 1.59 MB
Date posted: 4/25/2017
5. What to do next Ask your doctor about screening tests Estimate your risk Keep your weight in check Learn your family medical history Connect with relevant groups Talk with a genetic counselor
13. Conclusion DTC genetic industry—like the entire genetic industry— needs a clear and rational regulatory oversight framework that also allows companies to contribute meaningfully to personalized medicine and improved health care .
Editor's Notes
We offer a variety of health information.
3 rd point: physician is necessary to the process info. We do not argue with this but we think there are other ways as well. We are providing tools to minimize the chance of both of these outcomes. We give our data in context. As you can see here, when a person gets their data, they are comparing the average person’s risk against their own risk. We also provide extensive information about the condition and we give them steps on what to do next; these steps include encouraging consumers to discuss their results with their physician and to speak with a genetic counselor. Besides this, we have a myriad of tools to help educate consumers about their genetic information. My colleague will discuss our education in a later session. Reveal is also beginning a trial now to study the topic of how people handle the information with and without physicians as intermediaries.
3 rd point: physician is necessary to the process info. We do not argue with this but we think there are other ways as well. We are providing tools to minimize the chance of both of these outcomes. We give our data in context. As you can see here, when a person gets their data, they are comparing the average person’s risk against their own risk. We also provide extensive information about the condition and we give them steps on what to do next; these steps include encouraging consumers to discuss their results with their physician and to speak with a genetic counselor. Besides this, we have a myriad of tools to help educate consumers about their genetic information. My colleague will discuss our education in a later session. Reveal is also beginning a trial now to study the topic of how people handle the information with and without physicians as intermediaries.
We will be listening today, have been thinking about this and will be sharing Ideas with FDA Friday
DTC Industry needs clear and rational regulatory oversight framework to thrive and contribute meaningfully to personalized medicine